Antigen-expressing eDC line

CATALOG NUMBER · CR-C54-4

MD54.4
NY-ESO-1-expressing eDC line

A renewable human APC research tool expressing full-length NY-ESO-1, typed HLA-A*02:01 / HLA-A*24:02.

Overview

MD54.4 is an antigen-expressing eDC line designed for NY-ESO-1-related antigen presentation and T cell research. It expresses the whole NY-ESO-1 protein, so epitopes arise through the eDC’s own antigen processing instead of being supplied as a fragment or peptide, creating a defined starting configuration for testing an immune response.

All MD54 lines are typed HLA-A*02:01 / HLA-A*24:02. The series is therefore suitable for studying HLA-A*02:01- or HLA-A*24:02-restricted antigen presentation. Expression of the full-length antigen does not by itself establish processing or presentation of a given epitope in either HLA context. These questions require peptide-specific and functional evidence.

For drug target discovery, connect the APC configuration to an appropriate effector population and target cell model. HLA blockade, antigen controls and viability measurements help distinguish recognition from nonspecific changes in assay signals.

Technical specifications

AttributeCurrent information
Product name / catalog numberMD54.4 · NY-ESO-1-expressing eDC line · Cat. No. CR-C54-4
Antigen constructFull-length NY-ESO-1 (whole antigen); construct details to be added
HLA typingHLA-A*02:01 / HLA-A*24:02
Cell systemHuman eDC line in an antigen-expressing configuration
Format & quantityTo be specified for MD54.4
Expression / presentation evidenceAntigen expression characterization and peptide-specific presentation evidence to be added
Quality documentationLine identity, mycoplasma testing, microbiological testing and culture performance documentation to be added for the offered material
Recommended passage windowTo be established from growth and functional characterization of the line

Growth conditions & culture development

MD54.4 culture support is being developed as a growth factor cocktail. The formulation must be evaluated for cell recovery, viability, growth, antigen expression and APC function across the intended culture interval.

Culture attributeDevelopment information
Basal medium referenceMD54 source line documentation lists RPMI 1640 with 10% FBS, or X-VIVO with 5% serum replacement. Final MD54.4 conditions remain to be confirmed.
Vessel & starting densitySource line reference: T25 flask; 0.5–1.5 × 106 cells/mL. These are development starting conditions, not a validated MD54.4 protocol.
Medium renewalSource line reference: approximately 2–3 times per week; optimize for the chosen cocktail and cell density trajectory.
Proposed growth factor cocktailIL-2-Fc4, IL-15SA-Fc4 and FLT3L-Fc4 are candidate components. Final composition, activity units, concentrations and feeding schedule are under development.
Growth patternAdherent growth is described for the MD54 source line family; assess morphology and recovery for the engineered MD54.4 configuration.
Handling & release documentationFinal instructions will define thawing, culture support, recovery, sampling and product-specific testing.
Under development

No optimized cocktail recipe or performance specification is presented here. Source line culture details guide development and must be verified for the antigen-expressing product.

Data & Figures

Data to be added

Functional research data for MD54.4 are not yet published on this page.

Product documentation

DocumentStatus
MD54.4 product information sheetContent reserved
HLA typing and NY-ESO-1 specificationContent reserved
Culture & handling instructionsUnder development
Characterization and quality report for the lineContent reserved

Product documentation will distinguish configuration information from lot-specific testing.

Publications

PNAS · 2018

Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells

Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H. 115(19):E4453–E4462. DOI: 10.1073/pnas.1800550115.

View publication
Cancer Immunology, Immunotherapy · 2025

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity

Zhao C et al. 74:117. DOI: 10.1007/s00262-025-03971-y.

View publication

Selected publications provide scientific context. Consult the documentation for the specific eDC configuration when assessing product suitability.

Planning an NY-ESO-1 experiment?

Discuss HLA compatibility, effector cells, targets and study controls.

Scientific support